Articles from Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

– Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups –

By Rivus Pharmaceuticals, Inc. · Via GlobeNewswire · November 7, 2025

Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®

First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s

By Rivus Pharmaceuticals, Inc. · Via GlobeNewswire · November 4, 2025